Literature DB >> 35040302

Gut microbiota in inflammatory bowel disease: a target for therapy not to be missed.

Tiziana Larussa1, Ludovico Abenavoli2, Giulia Fabiano2, Maria A Mancuso2, Natale Polimeni3, Dan L Dumitrascu4, Francesco Luzza2.   

Abstract

In the last years, the gut microbiota achieved great importance, since several studies demonstrated its correlation with the immune system and with the maintenance of intestinal homeostasis, as well as with the regulation of the integrity of the epithelium and the intestinal motility. An imbalance in microbial species promotes a dysbiosis, which has been associated with chronic diseases such as metabolic syndrome, inflammatory diseases, and some behavior disorders. The association with gut microbiota and dysbiosis has been demonstrated mostly in inflammatory bowel disease (IBD). Several studies investigated the application of antibiotics, prebiotics, probiotics, and fecal microbiota transplantation in the treatment strategies for IBD. In this review, we discuss the recent findings on the potential role of the gut microbiota manipulation, with particular attention to bacterial microbiota, which could be implicated for a successful IBD therapeutic approach.

Entities:  

Mesh:

Year:  2021        PMID: 35040302     DOI: 10.23736/S2724-5985.21.02907-7

Source DB:  PubMed          Journal:  Minerva Gastroenterol (Torino)        ISSN: 2724-5985


  3 in total

Review 1.  Role of gut microbiota-derived signals in the regulation of gastrointestinal motility.

Authors:  Zhipeng Zheng; Jingyi Tang; Yingnan Hu; Wei Zhang
Journal:  Front Med (Lausanne)       Date:  2022-07-22

2.  The Interplay Between Use of Biological Therapies, Psychological State, and the Microbiome in IBD.

Authors:  Paris Tavakoli; Ute Vollmer-Conna; Dusan Hadzi-Pavlovic; Xabier Vázquez-Campos; Michael Carl Grimm
Journal:  Front Med (Lausanne)       Date:  2022-07-19

3.  Trends in the Comprehension and Management of Gastrointestinal Tract Disorders.

Authors:  Marilena Durazzo; Arianna Ferro; Sharmila Fagoonee; Rinaldo Pellicano
Journal:  J Clin Med       Date:  2022-03-21       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.